



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 614 659 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 94301695.6

(51) Int. Cl.⁵: A61K 9/00, B65D 35/00

(22) Date of filing: 10.03.94

(30) Priority: 11.03.93 US 29443
30.08.93 US 114315

(43) Date of publication of application:
14.09.94 Bulletin 94/37

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: TARO PHARMACEUTICAL
INDUSTRIES LIMITED
14 Hakitor Street
IL-26110 Haifa Bay (IL)

(72) Inventor: Ross, Malcolm Stewart Frank
4 Pekil'in Street
Tel Aviv (IL)

(74) Representative: Ritter, Stephen David et al
Mathys & Squire
10 Fleet Street
London EC4Y 1AY (GB)

(54) Pharmaceutical compositions in semisolid form and a device for administration thereof.

(57) A pharmaceutical formulation in semisolid form useful for systemic treatment of an illness is disclosed, as well as a device for containing and measuring a unit dose of the formulation comprising a squeezable container having a cap with a spoon attached thereto and means for resealing the squeezable container after use. A child proof closure useful for the device is also disclosed.

EP 0 614 659 A2

Jouve, 18, rue Saint-Denis, 75001 PARIS

Background of the Invention

This invention is concerned with new formulations of orally active pharmaceutical agents and a device for administration thereof. More particularly this invention is concerned with formulations in semisolid form for oral administration of pharmaceutical agents used for systemic treatment, preferably contained in a single dose packet or in a multi-dose measuring device which can be used to measure as well as to administer the formulation, and to a childproof closure useful for the device.

Heretofore, pharmaceutical agents for systemic treatment by oral administration have generally been formulated in solid form as pills or capsules or in liquid form. Children, the elderly and people with motor problems often have problems swallowing pills and capsules. It is also difficult to administer medicine in liquid form to children, even when the liquid has been thickened to a syrup, and the elderly and those with motor problems also have difficulty with the self administration of liquid, especially when it is necessary to measure a specific unit dose.

Important requirements for a non-solid pharmaceutical formulation for oral administration include palatability to children and adults, stability, i.e. a long shelf life, compatibility of formulation components with active agent and desirably, ease of administration of the required dose.

Pharmaceutical preparations in semisolid form for topical application are well known in the art. Such preparations include gels, pastes, creams and ointments for use on the skin, teeth and mucous membranes. Antacids and anti-ulcer agents in suspension and gel form for coating the mucous lining of the stomach are also well known in the art.

In a few instances, systemically useful pharmaceutical agents have been incorporated into gelled vehicles, as for example those disclosed in U.S. Pat. Nos. 4,305,933, 4,576,645 and 4,883,660. However, these vehicles all suffer from one or more disadvantages, such as the presence of a component which is undesirable for administration to children and/or is incompatible with many pharmaceutical agents, the presence of an emulsion which is difficult to manufacture and tends to be unstable and/or inadequate viscosity.

There is a need for an economical formulation of systemic pharmaceutical agents in easily administered form, as well as a need for easily administered non-spill pharmaceutical formulations which can be measured and administered effortlessly to children and by adults with motor problems. There is also a need for a simple to use and easily manufactured device for the measurement and administration of a predetermined dose of a pharmaceutical agent and also for a device of this type which is substantially tamper-proof in so far as young children or individuals with limited mental capacity are concerned.

While devices for dispensing a measured amount of a composition have been disclosed, for example in U.S. Pat. Nos. 3,104,032 and 3,383,081, these devices tend to be complicated and are not completely satisfactory for easy delivery and administration of a measured amount of a pharmaceutical composition.

35

Summary of the Invention

An object of the invention is the provision of pharmaceutical agents useful for systemic treatment by the oral route in a form which is convenient to administer to children and which is convenient for self administration of aging adults, as well as adults with motor problems.

Another object of the invention is the provision of pharmaceutical agents useful for systemic treatment by oral administration in a composition which is provided in a device from which it is particularly easy to administer and convenient to measure single dosage units of the composition.

A further object of the invention is the provision of pharmaceutical agents useful for systemic treatment by oral administration in a form which avoids the problems of liquid formulations, such as spillage.

Another important object of the invention is the provision of a device for easily administering pharmaceutical formulations in semisolid form in dosage units.

Still another important object of the invention is the provision of a device for easily administering pharmaceutical formulations in semisolid form in dosage units which is substantially tamper proof by young children or individuals with limited mental capacity.

A further important object of the invention is the provision of a childproof closure useful for a device for holding pharmaceutical formulations.

These and other objects of the invention are achieved by the invention set forth below.
It has been discovered that pharmaceutical agents in semisolid form, such as a gel or paste, are much easier to administer to children than liquid and solid dosage forms and are much easier for an aging adult or a adult with motor problems to measure than a liquid and in some cases are easier to swallow than a pill or capsule. It has also been discovered that such compositions can be desirably packaged in a single dosage form or in a multi-dose device which contains measuring and administration means.

According to the invention, a pharmaceutical agent useful for oral administration to treat an illness systematically is provided as a semisolid in gel or suspension form, such as a paste, in a composition containing the pharmaceutical agent and a pharmaceutically acceptable vehicle comprising a thickening agent and a liquid base compatible with the pharmaceutical agent and thickening agent in which the pharmaceutical agent is soluble.

5 In a preferred embodiment of the invention, a single dose of the semisolid pharmaceutical composition is contained in a flexible packet which can be opened by tearing or cutting.

10 In another preferred embodiment of the invention, a device for containing the semisolid pharmaceutical composition is provided which comprises a squeezable container with means for measuring and administering therefrom a single dose of the semisolid composition of the invention and resealing the container thereafter.

15 In a particularly preferred embodiment of the invention, a device for containing multiple doses and measuring a single dose of the semisolid composition of the invention comprises a squeezable container for holding the pharmaceutical composition having an open neck with exterior threads for attaching a cap thereto and a cap with interior threads suitable to engage the outer threads of the neck of the squeezable container, a spoon having a shaft with channel means fixed in the cap so that the bowl-shaped end of the spoon projects outside the cap and the shaft projects into the cap and the channel means are in alignment with the open neck of the squeezable container and sealing means in said cap positioned to seal the container when the cap is fully closed and to provide space for the contents of the container to flow through the channel means into the spoon in response to pressure on the container when the cap is partially opened, whereby contents of the squeezable 20 container can be squeezed into the bowl-shaped end of the spoon and administered therefrom.

25 The device of the invention can be resealed after use by including any of a variety of resealing means in the cap, such as pin inside the cap which rests against and closes the neck of the squeezable container when the cap is tightened after use; a rotatable or pivotable valve and a spring activated step valve, which allow passage of the semisolid composition from the tube to the spoon when open and seal off the contents of the squeezable container when in the closed position.

Another embodiment of the invention is a closure which cannot be normally opened normally by a child, which is referred to herein as a childproof closure, and which can be used in the device of the invention.

Brief Description of the Drawings

30 Figure 1 illustrates a closed tube containing a semisolid composition of the invention; Figure 2 illustrates a replacement cap of the invention for the tube of Figure 1 equipped with a spoon for measuring and administering a dose of the semisolid composition of the invention; Figure 3 illustrates a tube containing the semisolid composition of the invention with attached replacement cap equipped with a spoon and Figure 4 shows a section of Figure 3 along lines 4-4.

35 Figure 5 illustrates an alternate device of the invention having a resealable cap equipped with a spoon. Figure 6, which illustrates the cap in closed position and Figure 7, which illustrates the cap in open position with semisolid composition of the invention being squeezed into the spoon, show sections of the cap of Figure 5 taken along the line 7-7.

40 Figure 8 is a perspective view of a cap, partially broken away to reveal the inner structure of the resealing mechanism of another embodiment of the device of the invention; Figure 9 shows a section of the cap of Figure 8 taken along the line 9-9.

45 Figure 10 is a perspective view of a cap, partially broken away to reveal the inner structure of the pivoting valve resealing mechanism of another embodiment of the device of the invention; Figure 11 is a partial side view of the pivoting valve with a phantom outline of the pivoting valve in the upright closed position shown by the dash-dot line and the open position by the dashed line.

Figure 12 is a perspective view of a cap, partially broken away to reveal the inner structure of a cap with a spring-activated mechanism of another embodiment of the device of the invention; Figure 13 shows a section of Figure 12 along the line 12-12.

50 Figure 14 is another perspective view of a cap, partially broken away to reveal the inner structure of resealing means with a spring-activated mechanism of another embodiment of the device of the invention, which is further provided with means to prevent access of the contents of the tube to children and to prevent tampering; Figure 15 shows a section of Figure 14 taken along line 15-15 which illustrates means to prevent access of the contents of the tube to children and Figure 16 also shows a section of Figure 14 taken along line 15-15 which illustrates means to prevent tampering of the device prior to intended use.

Description of the Invention

The pharmaceutical compositions of the invention are comprised of a pharmaceutical agent in an effective amount for systemic treatment by oral administration in admixture with a pharmaceutically acceptable vehicle comprising a thickening agent in an amount which provides a semisolid, such as a gel or a paste suspension. The semisolid has a Brookfield viscosity at of above 2500 cps, preferably 2500 to 70,000 cps more preferably 3500 - 65,000 cps and most preferably about 7,500 - 40,000 cps. In the present application, viscosity refers of Brookfield viscosity, measured at 25°C and a spindle speed of 10 rpm, unless otherwise noted.

5 The semisolid form is generally a gel or a paste suspension which has the required viscosity to be squeezable easily through a small orifice similarly to tooth paste, dermatological creams, ointments and the like. The particular viscosity above 2500 cps is not critical as long as it fulfills the requirement of being a semisolid which is squeezable through a relatively small orifice such as that usual at the mouth of a flexible tube.

10 In general, the viscosity of the compositions of the invention can be varied by the choice and amount of thickening agent used from about 2500 cps to any greater viscosity which still permits the composition to be readily squeezed through a relatively narrow orifice, i.e. of the order of about 1 to 5 mm in diameter, such as that provided by the opening of a single dose packet or a seal-a-spoon device of the invention.

15 By systemic treatment is meant treatment which affects the body as a whole, as compared to topical treatment, which affects only that part of the body to which it is applied, i.e. skin, teeth or particular mucous membrane, such as the lining of the stomach.

20 Orally active pharmaceutical agents which may be present in the semisolid compositions of the invention are those useful for systemic treatment by oral administration and include for example:

analgesics, such as acetaminophen, codeine, aspirin and dihydrocodeinone;

anti-inflammatory agents, such as ibuprofen, naproxen and diclofenac;

25 anti-histamines including H₁-blockers, such as chlorpheniramine, terfenadine, loratadine, astemizole and cetirizine and H₂-blockers, such as cimetidine and ranitidine;

anti-infectives including: antibacterials such as sulfa drugs, i.e. sulfisoxazole; quinolones, i.e. ciprofloxacin and ofloxacin; tetracyclines, i.e. tetracycline; anti-virals, i.e. acyclovir and amantadine and anti-fungals, i.e. fluconazole;

bronchodilators, such as albuterol, metaproterenol and theophylline;

30 cough suppressants, such as dextromethorphan;

expectorants, such as guaifenesin;

CNS active agents, including: hypnotics, such as triazolam; sedatives, such as phenobarbital; tranquilizers, such as chlorpromazine and diazepam; antidepressants, such as fluoxetine and nortriptyline; anti-convulsants, such as carbamazepine and ethosuximide and anti-Parkinson's agents, such as L-DOPA;

35 cardiovascular drugs including: diuretics, such as hydrochlorthiazide; anti-hypertensives including: beta-blockers, such as propranolol; ACE inhibitors, such as captopril and enalapril; calcium channel blockers, such as diltiazem; anti-anginals, same as anti-hypertensive agents; cardiac glycosides, such as digoxin;

antineoplastics, such as 5-fluorouracil and cyclophosphamide;

cholesterol-lowering agents such as lovastatin;

40 anti-emetics, such as metoclopramide;

vitamins, such as A, B₁, B₆, C, D₃ and E;

minerals, such as iron, calcium and zinc salts and fecal softeners, such as docusate.

Useful pharmaceutical agents of course include pharmaceutically acceptable salts and esters of the named compositions.

45 The semisolid compositions of the invention have a liquid base, which is a palatable pharmaceutically acceptable solvent, preferably a solvent which dissolves the active pharmaceutical agent. Preferred solvents include water, propylene glycol, glycerin and mixtures thereof. In some instances it may be necessary to include a compound which is effective to solubilize the active pharmaceutical agent in the solvent, for example, lactic acid is used in an aqueous formulation of ciprofloxacin hydrochloride to solubilize this active ingredient.

50 According to the invention, any pharmaceutically acceptable thickening agent can be used in the compositions of the invention, providing of course that the thickening agent is compatible with the active agent and the solvent base. Examples of useful thickening agents include natural occurring thickening agents or thickening agents derived from naturally occurring materials, such as starch and starch derivatives, for example modified starch; cellulose derivatives, for example sodium carboxymethylcellulose, microcrystalline cellulose

55 and hydroxypropyl cellulose; acacia; tragacanth, pectin and gelatin, as well as totally synthetic thickeners, such as polyethylene glycol and water soluble carboxyvinyl polymers, such as those sold under the names of carbomer and Carbopol™, which is produced by B. F. Goodrich Chemical Group. Gelatin, cellulose derivatives, polyethylene glycols and water soluble carboxyvinyl polymers are preferred.

A sweetener is added to the composition of the invention in an amount necessary to make the semisolid palatable.

Ingredients such as flavoring, coloring matter, filler, preservative, buffer, sodium chloride and carriers usual in pharmaceutical compositions can also be present in the semisolid compositions of the invention.

5 In one preferred embodiment, a single dose of the semisolid pharmaceutical composition of the invention is contained in a small flexible packet or sachet which is readily torn or cut so that the contents thereof can be squeezed directly into the mouth, or if preferred, into another vehicle for oral administration. Such a container is commonly used, for example, for single servings of condiments and can be made of flexible plastic and/or of non-corrosive metal film.

10 In another preferred embodiment, multiple doses of the semisolid pharmaceutical composition of the invention are contained in a device of the invention referred to as a seal-a-spoon which is described in detail below and in the accompanying drawings.

15 With reference to Figures 1-4, the tube 1 containing a semisolid pharmaceutical composition of the invention is provided with the cap 3, which can be replaced by the cap 5 shown in Figure 2. The device with attached cap 5 is illustrated in Figures 3 and 4. As is usual, the outside of neck 2 of tube 1 and the inside of cap 5 are provided with corresponding threads, so that the cap can be fixed to the neck of the tube. A spoon shaped projection 7, which is preferably sized to contain a single unit dose of the semisolid composition of the invention contained in tube 1, is connected to the cap 5 by means of the shaft 9, which is provided with a channel 11 adapted to be aligned with the opening of the neck 2 of tube 1, so that the semisolid composition in tube 1 can be squeezed directly from the tube 1 through the channel 11 into the spoon shaped projection 7 and administered therefrom.

20 Seal-a-spoon devices of the invention wherein the cap containing the spoon-shaped projection is provided with resealable means are illustrated in Figures 5-15. A seal-a-spoon device of the invention with a "child-proof" mechanism and also with tamper-proof means is illustrated in Figures 14-16.

25 As illustrated in Figures 5-7, the spoon shaped projection 7 set in cap 5a by shaft 9 is provided with a pin 13 which projects into the inside of the cap 5a and is adapted to rest against the neck 2 of tube 1 and seal the tube when the cap 5a is in the fully closed position illustrated in Figure 6. When the cap is rotated a few notches, as illustrated in Figure 7, but not separated from tube 1, the pin no longer rests against the neck of tube 1, which is then unsealed and the semisolid composition in tube 1 can be readily forced through the channel 15, which is present between the shaft 9 and the pin 13, into the projecting spoon 7 and administered directly therefrom.

30 Another embodiment of the seal-a-spoon device of the invention is illustrated in Figures 8 and 9 wherein the cap 5c is provided with the rotating valve or stopcock 17 having a channel 19 which can be aligned as shown with the channel 11 in the shaft 9 (not shown) or turned to prevent the flow of semisolid composition from the tube 1, as indicated by the dashed line in Figure 9.

35 Still another embodiment of the seal-a-spoon device of the invention is illustrated in Figures 10 and 11, wherein the cap 5d is provided with the pivoting valve 21 connected to the pivoting hinge 23. The pivoting valve 21 has a channel 25 which is in alignment with the channel 11 of the shaft 9 (not shown) when in the down position illustrated, allowing the flow of semisolid composition from the tube 1 (not shown) into the spoon 7; when the pivoting valve 21 is moved to the upright position, as shown by the dash-dot line of Figure 11, with the aid of the protuberance 27, the contents of the tube 1 are resealed.

40 Further embodiments of the seal-a-spoon device of the invention are illustrated in Figures 12-15. As shown in Figures 12 and 13, the cap 5e is provided with a spring biased step cylinder 29 having a channel 31; the spring 33 is held in place by a retaining member 35, such as a screw plug. When the step cylinder 29 is in the normal upright position, the contents of tube 1 (not shown) are sealed; when the step cylinder 29 is pressed to compress the spring 33, so that the channel 31 is in alignment with the channel 11 of the shaft 9 (not shown), the contents of the tube 1 (not shown) can be squeezed into the spoon 7.

45 A childproof and tamper proof seal-a-spoon device of the invention is illustrated in Figures 14-16, wherein the cap 5f is provided with a rotating spring biased step cylinder 37 having a channel 39 and also having on its side, near the top, the button 41. The cap 5f is also provided on its outside near the step cylinder 37, with a cavity 43 corresponding in size and shape to the button 41. When the step cylinder 37 is in the normal upright position, the contents of the tube 1 (not shown) are sealed. The step cylinder 37 cannot be depressed unless the button 41 is lined up with the cavity 43 in the cap 5f. In addition, the cavity in the cap 5f is initially sealed with a sheet of plastic 45. When the button is aligned with the cavity of corresponding shape in the cap 5f and pushed for the first time, the plastic sheet 45 is broken. An unbroken sheet 45 means that the cap 5f has not been previously used or tampered with. The cap 5f is a permanent cap which can not be removed by normal means or which has special safeguards against removal.

50 Since the rotating spring biased cylinder 37 cannot be depressed unless the button 41 is first lined up with

the cavity 43 in the cap 5f, three different motions are required before the contents of the tube 1 (not shown) can be caused to flow into the spoon 7: aligning the button 41 with the cavity 43 by rotating the step cylinder 37, depressing the step cylinder 37 to align the channel 39 with channel 11 and pressing on the tube 1 to effect the flow of semisolid composition from the tube to the spoon 7. Therefore, this embodiment of the seal-a-spoon device of the invention is considered to be child proof, as well as tamper proof.

The childproof closure illustrated in Figures 14, with or without (not illustrated) the projecting spoon, can be applied to other containers of medicine.

The following examples further illustrate the invention, but must not be construed as limiting the invention in any manner.

Example 1

Acetaminophen Formulation Thickened with Polyethylene Glycols

Acetaminophen was dissolved in a minimum quantity of water and combined with propylene glycol, a mixture of polyethylene glycols (PEG 400, which has an average molecular weight of 800 and PEG 3350, which has an average molecular weight of 1600), preservative, sweetener and flavoring to provide the following composition in percent by weight.

PEG mixture	72
Acetaminophen	2.5
Propylene glycol	25
Methylparabens	0.22
Sodium Saccharin	0.2
Cherry essence	0.05
Red DC 33	0.005
Water	to 10

PEG mixtures were varied in the foregoing formula to provide compositions with different viscosities as shown in Table 1. The viscosities were measured by means of a Brookfield Viscometer at 20°C at a spindle speed of 20 to 100 rpm, depending on medium viscosity, or at 25°C at a spindle speed of 10 rpm. All of these compositions are useful as semisolids for oral administration and can be packed in single dose containers or in a multiple dose device of the invention.

Table 1

PEG 400 % by wt.	PEG 3350 % by wt	VISCOSITY CPS
60	40	62,640
70	30	39,280
80	20	25,040

Example 2

Pseudoephedrine HCl Formulation Thickened with Polyethylene Glycols

Pseudoephedrine HCl (0.6%) is incorporated into a formulation base consisting of propylene glycol (25%), polyethylene glycols (73.5%) consisting of 75% PEG 400 and 25% PEG 3350, methyl parabens (0.22%) as a preservative, sodium saccharin (0.2%) as a sweetener, coloring and flavoring matter and water to make 100%.

This formulation provides a semisolid of desirable consistency and viscosity which can be packed in a single dose container or a seal-a-spoon device of the invention.

Example 3

Acetaminophen Formulation Thickened with Carboxymethylcellulose

Acetaminophen (3.2%) is dissolved in a minimum quantity of water, glycerin (4%) and propylene glycol (25%) are added, after which, sodium saccharin (0.2%), methyl parabens (0.22%) and sodium carboxymethyl-

cellulose (2.4%) are incorporated. Water is then added to make up 100%.

This formulation has a viscosity of 15,000 cps when measured in the same manner as the formulations of Example 1 and has a desirable semisolid consistency useful in packaging in single dose packets or in a multiple dose device of the invention.

5

Example 4

Dextromethorphan Hydrobromide Formulation Thickened with Carbopol™

10 Dextromethorphan HBr (0.3%) is dissolved in a mixture of propylene glycol (25%), glycerin (4%) and Carbopol 934P (1%) as a thickening agent. Sweetener, preservative, flavor and color as in Example 1 are optionally added and the mixture is made up to 100% with water. This formulation exhibited a viscosity of 15,000 cps, when measured at 20-21°C as in Example 1 and had a desirable semisolid consistency suitable for packaging into single dose packets or in a seal-a-spoon device of the invention.

15

Example 5

Dextromethorphan Hydrobromide Formulation Thickened with Gelatin

20 A pharmaceutical base is prepared by heating gelatin (2.5%) in water. Glycerin (4%), propylene glycol (25%) and dextromethorphan HBr (0.3%) are mixed into the gelatin solution. Sodium saccharin, methyl parabens, flavor and coloring matter are added as in Example 1 and the formulation is made up to 100% with water. This formulation exhibited a viscosity of 7500 which is suitable for packaging into single packets or a seal-a-spoon device of the invention. The viscosity of this formulation can be increased or decreased within the range of 6000 - 9000 cps by the addition of more or less gelatin.

25

Example 6

Carbidopa/Levidopa Formulation Thickened with Polyethylene Glycols

30

This is a non-aqueous formulation of carbidopa/levidopa, which is useful as an anti-Parkinson medicament containing the following ingredients.

35

	weight %/volume
Carbidopa	0.100
Levidopa	1.000
PEG 400	56.524
PEG 3350	29.120
Propylene glycol	13.000
Saccharine Sodium	0.250
FDC Red #40	0.006

40

45

50

The formulation, which is prepared by combining the polyethylene glycols with propylene glycol, sweetener and coloring matter and then adding the active agents thereto, has a consistency suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 7

Ibuprofen Formulation Thickened with Sodium Carboxymethylcellulose

55

This semisolid suspension, which contains a non-steroidal anti-inflammatory agent, has the following ingredients and is prepared as indicated in Example 6 by combining the components of the semisolid vehicle and then adding the active constituent thereto.

	Weight %/Volume
5	Ibuprofen 2.000
10	Citric Acid 0.200
15	ETDA (Disodium) 0.020
20	FDC red #40 0.006
	Cherry flavor 0.150
	Vanilla flavor 0.050
	Glycerin 20.000
	Sodium carboxymethylcellulose 2.400
	Sodium benzoate 0.100
	Hydrogenated glucose 6.5
	Purified water to 100 cc

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

25 **Example 8**

Terfenadine Formulation Thickened with Sodium Carboxymethylcellulose

30 A semisolid suspension of terfenadine, which is useful for the systemic treatment of allergies, is prepared as in Example 7 with the following ingredients.

	Weight %/Volume
35	Terfenadine 0.600
40	Sodium carboxymethylcellulose 2.400
45	Saccharin sodium 0.250
	Hydrogenated glucose 65.000
	Imitation raspberry flavor 0.150
	Methyl paraben 0.200
	Propyl paraben 0.050
	FDC yellow #10 0.006
	Purified water to 100 cc

50 The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 9

Ranitidine Formulation Thickened with Sodium Carboxymethylcellulose and Hydroxypropyl Methylcellulose

55 A semisolid formulation of ranitidine, which is an antagonist to histamine H₂ receptors, is prepared as in Example 7 with the following ingredients.

	Weight %/Volume
5	Ranitidine HCl (1.5% Ranitidine) 1.680
	Dibasic sodium phosphate 0.030
	Sodium carboxymethylcellulose 2.400
	Hydroxypropyl methylcellulose 0.900
10	Peppermint flavor 0.100
	FDC yellow #10 0.006
	Monobasic potassium phosphate 0.020
15	Butyl paraben 0.180
	Propyl paraben 0.500
	Sodium chloride 0.050
20	Sorbitol 70% 30.000
	Purified water to 100 cc

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

25

Example 10

Ciprofloxacin HCl Formulation Thickened with Sodium Carboxymethylcellulose

30

A semisolid formulation of ciprofloxacin HCl, which is an antimicrobial agent, is prepared according to Example 7 with the following ingredients. In this formulation lactic acid is used to solubilize Ciprofloxacin HCl and the pH is adjusted to between 3.5 - 4.6 with HCl.

35

	Weight %/Volume
	Ciprofloxacin HCl (200 mg Ciprofloxacin) 10.000
	Saccharin sodium 0.250
40	Lactic acid 0.020
	Sodium carboxymethylcellulose 2.400
	Blackberry flavor 0.150
45	FDC red #40 0.006
	FDC red # 5 0.002
	Dextrose solution (5 %) in purified water to 100 cc

40

50

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention

55

Example 11

Triazolam Formulation Thickened with Sodium Carboxymethylcellulose

A semisolid formulation of triazolam, a hypnotic useful against insomnia, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
5	Triazolam 0.005
	Sodium Benzoate 0.250
10	FDC yellow #6 0.008
	Imitation orange flavor 0.120
15	Sodium Saccharin 0.220
	Sodium carboxymethylcellulose 2.800
	Hydrogenated glucose 20.000
	Purified water to 100 cc

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

20 **Example 12**

Fluconazole Formulation Thickened with Sodium Carboxymethylcellulose

25 A semisolid formulation of fluconazole, a broad spectrum antifungal agent, was prepared as in Example 7 with the following ingredients.

	Weight %/Volume
30	Fluconazole 2.000
	Sodium carboxymethylcellulose 2.400
35	FDC red #40 0.006
	Cherry flavor 0.150
	Sodium saccharin 0.240
	Sodium chloride 0.050
	Purified water to 100 cc

40 The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention. The formulation should be stored at a temperature below 25°C, but not lower than 5°C and must be supplied in a container made of polyvinyl chloride, Baxter Vialflex.

45 **Example 13**

Acyclovir Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose

50 A semisolid formulation of acyclovir, an anti-viral agent, is prepared according to Example 7, with the following ingredients.

	Weight %/Volum
5	Acyclovir 4.000
10	Methyl paraben 0.100
15	Propyl paraben 0.020
20	Sodium carboxymethylcellulose 2.400
	Peppermint flavor 0.150
	Glycerin 20.000
	Microcrystalline cellulose 0.900
	Sorbitol 70% 20.000
	Sodium saccharin 0.30
	FDC yellow #6 0.008
	Purified water to 100 cc

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

25 **Example 14**

Fluoxetine HCl Formulation Thickened with Sodium Carboxymethylcellulose

A semisolid formulation of fluoxetine hydrochloride, and anti-depressant drug, is prepared according to 30 Example 7 with the following ingredients.

	Weight %/Volume
35	Fluoxetine HCl 0.400
40	Benzoic acid 0.200
45	Imitation cherry flavor 0.150
	FDC red #40 0.006
	Glycerin 30.000
	Sodium saccharin 0.200
	Methyl paraben 0.160
	Hydrogenated glucose 65.000
	Sodium carboxymethylcellulose 2.500
	Purified water to 100 cc

50 The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 15

Propranolol HCl Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose

A semisolid formulation of propranolol hydrochloride, which is a synthetic beta adrenergic receptor blocker,

is prepared according to Example 7 with the following ingredients.

		Weight %/Volume	
		20 mg/5cc	40 mg/5cc
5	propranolol HCl	0.400	0.800
	Cherry flavor	0.150	
10	Peppermint flavor		0.100
	FDC red #40	0.006	
	FDC yellow #6		0.008
15	Microcrystalline cellulose	0.900	0.900
	Sodium carboxymethylcellulose	2.400	2.400
	Methyl paraben	0.200	0.200
20	Propyl paraben	0.050	0.050
	Sodium saccharin	0.250	0.250
	Purified water to	100 cc	100 cc

25 The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 16

Enalapril Maleate Formulation Thickened with Sodium Carboxymethylcellulose

A semisolid formulation of enalapril maleate, which is useful for treatment of hypertension and heart failure, is prepared according to Example 7 with the following ingredients.

		Weight %/Volume	
		35	40
	Enalapril maleate	0.100	
	FDC red #40	0.007	
40	Saccharin sodium	0.250	
	Imitation cherry flavor	0.150	
	Sodium carboxymethylcellulose	2.800	
45	Methyl paraben	0.220	
	Purified water to	200 cc	

50 The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 17

Diltiazem HCl Formulation Thickened with Sodium Carboxymethylcellulose, Hydroxypropyl Cellulose and Polyethylene Glycol

A semisolid formulation of diltiazem hydrochloride, which is a calcium antagonist, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
5	Diltiazem HCl 0.600
	FDC yellow #6 0.006
	Peppermint flavor 0.100
10	Hydroxypropyl cellulose 0.900
	Sodium carboxymethylcellulose 2.400
	Hydrogenated glucose 60.000
	Saccharin sodium 0.220
15	Polyethylene glycol 1500 10.000
	Purified water to 100 cc

The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 18

Lovastatin Formulation Thickened with Sodium Carboxymethylcellulose and Polyethylene glycol

25 A semisolid formulation of lovastatin, a cholesterol lowering agent, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
30	Lovastatin 0.200
	Butylhydroxy toluene 0.200
	Sodium carboxymethylcellulose 2.500
35	FDC red #40 0.006
	Peppermint flavor 0.100
	Sodium saccharin 0.250
40	Polyethylene glycol 1500 25.000
	Methyl paraben 0.200
	Purified water to 100 cc

45

Claims

- 50 1. A pharmaceutical composition comprising a semisolid in the form of a gel or suspension containing an effective amount of an orally active pharmaceutical agent useful for systemic treatment in combination with a pharmaceutically acceptable vehicle consisting essentially of liquid base selected from a member of the group consisting of water, propylene glycol, glycerin and a combination thereof, thickening agent selected from a member of the group consisting of starch, sodium carboxymethyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, tragacanth, acacia, pectin, gelatin, polyethylene glycol and carbomer in an amount effective to provide Brookfield a viscosity of about 2500 to 70,000 cps and a consistency which allows the composition to be squeezed easily through an orifice of about 0.1 mm to 5 mm in diameter; sweetener, preservative and optionally, flavouring matter, colouring matter, buffer, sodium
- 55

- chloride and solubilising agent for the orally active pharmaceutical agent.
2. The pharmaceutical composition according to Claim 1, which has a Brookfield viscosity of 3500 to 65,000 cps at 25°C at a spindle speed of 10 rpm.
 5. The pharmaceutical composition according to Claim 1 or Claim 2, in which the pharmaceutical agent is selected from a member of the group consisting of an analgesic, non-steroidal anti-inflammatory, anti-histamine, cough suppressant, expectorant, bronchodilator, anti-infective, CNS active drug, cardiovascular drug, antineoplastic, cholesterol-lowering drug, anti-emetic, vitamin, mineral supplement and fecal softener.
 10. The pharmaceutical composition according to Claim 1, in which the pharmaceutical agent is selected from a member of the group consisting of acetaminophen, aspirin, ibuprofen, diphenhydramine, dextromethorphan, guaifenesin, pseudoephedrine, carbidopa/levodopa, terfenadine, ranitidine, ciprofloxacin, triazolam, fluconazole, acyclovir, fluoxetine, enalapril, diltiazem, lovastatin and a pharmaceutically acceptable salt or ester thereof.
 15. The pharmaceutical composition according to any preceding claim which is contained in a single dose packet.
 20. 6. A device for containing and measuring a unit dose of a pharmaceutical composition in semisolid form comprising a squeezable container for holding the pharmaceutical composition having an outlet defining a flow channel for delivering said composition from the container, and closure means adapted to be connected to the outlet, the closure means comprising a spoon-shaped element having a shaft with channel means connected thereto so that the bowl of the spoon-shaped element projects from the closure means and the channel means are in fluid communication with the flow channel of the squeezable container and sealing means in said closure means positioned to seal the container when the closure means is fully closed and to provide space for the contents of the container to flow through the channel means into the spoon-shaped element in response to pressure on the container when the closure means is partially opened, whereby contents of the squeezable container can be squeezed into the bowl of the spoon-shaped element and administered therefrom.
 25. 7. A device for containing and measuring a unit dose of a pharmaceutical composition in semisolid form comprising a squeezable container for holding the pharmaceutical composition having an open neck with threads for attaching a cap thereto and a cap with threads suitable to engage the threads of the neck of the squeezable container, a spoon having a shaft with channel means fixed in the cap so that the bowl-shaped end of the spoon projects outside the cap and the shaft projects into the cap and the channel means are in alignment with the open neck of the squeezable container and sealing means in said cap positioned to seal the container when the cap is fully closed and to provide space for the contents of the container to flow through the channel means into the spoon in response to pressure on the container when the cap is partially opened, whereby contents of the squeezable container can be squeezed into the bowl-shaped end of the spoon and administered therefrom.
 30. 8. A device according to Claim 7 wherein the open neck is provided with exterior threads and the cap is provided with interior threads.
 35. 45. 9. The device of any of Claims 6 to 8 wherein the spoon holds a unit dose of the semisolid composition present in the squeezable container.
 40. 50. 10. The device of any of Claims 6 to 9 in which the sealing means comprises a pin inside the channel means which projects into the cap so as to rest against the neck of the container and seal the container when the cap is fully closed due to complete engagement of the threads of the neck of the squeezable container and threads of the cap, but which allows for the passage of a composition from inside the squeezable container through the channel means to the spoon when the threads of the neck of the squeezable container and threads of the cap are only partially engaged.
 55. 11. The device of any of Claims 6 to 9, in which the sealing means comprises a valve positioned in said cap capable of allowing passage of a composition from inside the squeezable container when in the open position and resealing the squeezable container when in the closed position.

12. The device of Claim 11, wherein the valve is rotatable or pivotable.
13. The device of any of Claims 6 to 9, in which the sealing means comprises a spring biased step cylinder positioned in said cap with channel means which allows passage of a composition from inside the squeezable container when said spring biased step cylinder is pressed to compress the spring and which reseals the squeezable container when not pressed.
5
14. The device of any of Claims 6 to 9, in which the sealing means comprises a rotatable spring biased step cylinder positioned in said cap, said rotatable spring biased step cylinder having channel means and an outside button, said cap being provided with a cavity which matches the size and shape of said button so that said button can fit into said cavity, whereby the channel means allows passage of a composition from inside the squeezable container when said rotatable spring biased step cylinder is depressed and said rotatable spring biased step cylinder can be depressed only when said button is aligned with said cavity.
10
15. The device of Claim 14, which further comprises a plastic covering over said cavity which prevents tampering with said device before use.
15
16. A child proof device for containing a pharmaceutical composition useful for administration to children comprising a container with an open neck for holding said pharmaceutical composition, a cap fitted permanently on the neck of said container, a rotatable spring biased step cylinder positioned in said cap having channel means which allows for passage of said pharmaceutical composition through the cap when said rotatable spring biased step cylinder is pressed downward against the spring and seals the container when not pressed, a button on the exterior and near the top of said rotatable spring biased step cylinder and a cavity in the exterior of the cap adjacent to said rotatable spring biased step cylinder which matches the size and shape of said button, said button being positioned on said rotatable spring biased step cylinder so as to prevent the downward movement of said spring biased cylinder unless said button is aligned with said cavity.
20
17. An assembly comprising a pharmaceutical composition in semisolid form which comprises an effective amount of an orally active pharmaceutical agent useful for systemic treatment in combination with a pharmaceutically acceptable vehicle comprising a thickening agent in an amount effective to provide a Brookfield viscosity of about 2500 to 70,000 cps at 25°C at a spindle speed of 10 rpm contained in the device defined in any of Claims 6 to 16.
25
18. An assembly according to Claim 17 wherein the composition is as defined in any of Claims 1 to 5.
30

40

45

50

55

FIG. 1




FIG. 2




FIG. 3





FIG. 4








FIG. 8




FIG. 9




FIG. 10




FIG. 11

